IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 306 filers reported holding IONIS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.70 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $370,864 | +8.0% | 8,176 | -2.3% | 0.00% | – |
| Q2 2023 | $343,461 | +14.7% | 8,371 | -0.1% | 0.00% | – |
| Q1 2023 | $299,537 | -14.4% | 8,381 | -9.6% | 0.00% | – |
| Q4 2022 | $350,014 | -19.5% | 9,267 | -5.7% | 0.00% | – |
| Q3 2022 | $435,000 | +17.6% | 9,829 | -1.5% | 0.00% | – |
| Q2 2022 | $370,000 | +3.4% | 9,982 | +3.3% | 0.00% | – |
| Q1 2022 | $358,000 | +33.1% | 9,662 | +9.4% | 0.00% | – |
| Q4 2021 | $269,000 | -8.5% | 8,831 | +0.4% | 0.00% | – |
| Q3 2021 | $294,000 | -21.2% | 8,799 | -5.9% | 0.00% | – |
| Q2 2021 | $373,000 | -11.2% | 9,347 | -0.1% | 0.00% | – |
| Q1 2021 | $420,000 | -13.8% | 9,358 | +8.7% | 0.00% | – |
| Q4 2020 | $487,000 | +20.2% | 8,606 | +0.8% | 0.00% | – |
| Q3 2020 | $405,000 | -20.1% | 8,540 | -0.5% | 0.00% | -100.0% |
| Q2 2020 | $507,000 | +25.2% | 8,585 | +0.0% | 0.00% | 0.0% |
| Q1 2020 | $405,000 | -24.9% | 8,584 | -3.9% | 0.00% | 0.0% |
| Q4 2019 | $539,000 | +7.4% | 8,933 | +6.4% | 0.00% | 0.0% |
| Q3 2019 | $502,000 | -6.9% | 8,393 | +0.2% | 0.00% | 0.0% |
| Q2 2019 | $539,000 | -19.2% | 8,378 | +2.0% | 0.00% | 0.0% |
| Q1 2019 | $667,000 | +45.0% | 8,212 | -3.5% | 0.00% | 0.0% |
| Q4 2018 | $460,000 | +4.1% | 8,512 | -0.5% | 0.00% | – |
| Q3 2018 | $442,000 | +24.9% | 8,558 | +0.5% | 0.00% | – |
| Q2 2018 | $354,000 | -5.3% | 8,513 | +0.6% | 0.00% | – |
| Q1 2018 | $374,000 | -11.8% | 8,460 | +0.2% | 0.00% | – |
| Q4 2017 | $424,000 | +1.2% | 8,441 | +2.3% | 0.00% | – |
| Q3 2017 | $419,000 | 0.0% | 8,249 | +0.2% | 0.00% | – |
| Q2 2017 | $419,000 | +18.4% | 8,229 | -6.6% | 0.00% | – |
| Q1 2017 | $354,000 | -16.7% | 8,815 | -0.9% | 0.00% | – |
| Q4 2016 | $425,000 | +46.6% | 8,897 | +12.9% | 0.00% | – |
| Q3 2016 | $290,000 | +53.4% | 7,877 | -3.0% | 0.00% | – |
| Q2 2016 | $189,000 | -64.1% | 8,120 | -37.6% | 0.00% | -100.0% |
| Q1 2016 | $526,000 | -69.4% | 13,016 | -53.0% | 0.00% | -50.0% |
| Q4 2015 | $1,717,000 | – | 27,711 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tweedy, Browne Co LLC | 3,541,136 | $133,749 | 7.12% |
| Bellevue Group AG | 9,743,900 | $368,027,103 | 4.88% |
| M28 Capital Management LP | 126,300 | $4,770,351 | 4.55% |
| Sicart Associates LLC | 246,258 | $9,301,165 | 3.28% |
| Camber Capital Management LP | 1,925,000 | $72,707 | 2.49% |
| Privium Fund Management B.V. | 148,807 | $5,557,941 | 2.11% |
| Deep Track Capital, LP | 1,205,773 | $45,542,046 | 1.91% |
| BVF INC/IL | 1,121,809 | $42,370,726 | 1.79% |
| Orbimed Advisors | 1,993,600 | $75,298,272 | 1.44% |
| Parkman Healthcare Partners LLC | 141,115 | $5,329,914 | 1.42% |